Stay updated on Pembrolizumab in Biliary Tract Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Biliary Tract Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Biliary Tract Cancer Clinical Trial page
- Check4 days agoChange DetectedFooter now shows Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision number updated to v3.3.2, replacing the previous v3.2.0.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoved the banner warning about government funding potentially affecting up-to-date information and NIH Clinical Center operating status; no trial data or eligibility details were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check54 days agoChange DetectedThe update appears to be formatting changes to the Study Details page without altering core trial information (eligibility criteria, endpoints, status, or enrollment); these differences are cosmetic and do not modify the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check83 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference4%

- Check90 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Biliary Tract Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Biliary Tract Cancer Clinical Trial page.